Marksans Pharma Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Mark Saldanha
Chief Executive Officer (CEO)
₹52.2m
Compensación total
| Porcentaje del salario del CEO | 92.0% |
| Permanencia del CEO | 8.7yrs |
| Participación del CEO | 43.8% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 5.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Many Still Looking Away From Marksans Pharma Limited (NSE:MARKSANS)
Aug 05If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Jul 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | ₹3b |
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹52m | ₹48m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹2b |
| Sep 30 2022 | n/a | n/a | ₹2b |
| Jun 30 2022 | n/a | n/a | ₹2b |
| Mar 31 2022 | ₹38m | ₹35m | ₹2b |
| Dec 31 2021 | n/a | n/a | ₹2b |
| Sep 30 2021 | n/a | n/a | ₹2b |
| Jun 30 2021 | n/a | n/a | ₹3b |
| Mar 31 2021 | ₹10m | ₹10m | ₹2b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹10m | ₹10m | ₹1b |
| Dec 31 2019 | n/a | n/a | ₹879m |
| Sep 30 2019 | n/a | n/a | ₹834m |
| Jun 30 2019 | n/a | n/a | ₹780m |
| Mar 31 2019 | ₹10m | ₹10m | ₹804m |
| Dec 31 2018 | n/a | n/a | ₹666m |
| Sep 30 2018 | n/a | n/a | ₹582m |
| Jun 30 2018 | n/a | n/a | ₹463m |
| Mar 31 2018 | ₹12m | ₹10m | ₹358m |
Compensación vs. Mercado: La compensación total de Mark($USD626.10K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD381.60K).
Compensación vs. Ingresos: La compensación de Mark ha aumentado más de un 20% en el último año.
CEO
Mark Saldanha (52 yo)
8.7yrs
Permanencia
₹52,161,600
Compensación
Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Non-Independent Executive Chairman & MD | 8.7yrs | ₹52.16m | 43.8% ₹ 31.0b | |
| Whole-time Director | 9.8yrs | ₹7.03m | 0.073% ₹ 51.6m | |
| Whole-time Director | 5.4yrs | ₹15.25m | sin datos | |
| Non-Executive Director & Non-Independent | 2.8yrs | sin datos | sin datos | |
| Non-Executive & Independent Director | 4.9yrs | ₹40.00k | sin datos | |
| Independent Director | 1.1yrs | sin datos | sin datos | |
| Non-Executive & Independent Director | 12.7yrs | ₹40.00k | sin datos | |
| Non-Executive Independent Director | 6.3yrs | ₹200.00k | sin datos |
5.8yrs
Permanencia media
53.5yo
Promedio de edad
Junta con experiencia: La junta directiva de MARKSANS se considera experimentada (5.7 años de antigüedad promedio).